Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value Health, pp.830-871, 2008. ,
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990, Journal of Infectious Diseases, vol.167, issue.5, pp.1247-51, 1980. ,
DOI : 10.1093/infdis/167.5.1247
Invasive Fungal Infections, Drugs, vol.21, issue.6, pp.65-73, 2009. ,
DOI : 10.2165/11315530-000000000-00000
Epidemiology and microbiology of nosocomial pediatric candidemia at a northern indian tertiary care hospital. Mycopathologia, 2011. ,
??valuation de l???adh??sion au r??f??rentiel Afssaps sur les antifongiques, en h??mato-oncologie p??diatrique, M??decine et Maladies Infectieuses, vol.41, issue.1, pp.25-32, 2011. ,
DOI : 10.1016/j.medmal.2010.09.012
Epidemiology, outomes, and costs of invasive aspergillosis in immunocompromised children in the United States, Pediatrics, vol.117, issue.4, pp.711-717, 2006. ,
Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Rev Anti Infcet Ther, Feb, vol.8, issue.2, pp.127-162, 2010. ,
Epidemiology of invasive fungal infections in neonates and children, Clinical Microbiology and Infection, vol.16, issue.9 ,
DOI : 10.1111/j.1469-0691.2010.03288.x
A Four-Year Review of Fatal Aspergillosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.18, issue.1, pp.42-47, 1999. ,
DOI : 10.1007/s100960050224
INVASIVE ASPERGILLOSIS IN CRITICALLY ILL PATIENTS: ANALYSIS OF RISK FACTORS FOR ACQUISITION AND MORTALITY, Acta Clinica Belgica, vol.26, issue.376, pp.251-258, 2004. ,
DOI : 10.1016/j.jhin.2004.01.006
Nosocomial fungal infections: epidemiology, diagnosis, and treatment, Medical Mycology, vol.45, issue.4, pp.321-367, 2007. ,
DOI : 10.1080/13693780701218689
Traitements antifongiques des candid??mies chez les patients non neutrop??niques??: ??valuation des pratiques en r??animation, M??decine et Maladies Infectieuses, vol.40, issue.11, pp.644-653, 2010. ,
DOI : 10.1016/j.medmal.2010.06.007
Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer, Jul1, vol.56, issue.7, pp.1092-1099, 2011. ,
Newer Systemic Antifungal Agents, Drugs, vol.49, issue.3, pp.1997-2020, 2004. ,
DOI : 10.2165/00003495-200464180-00001
Pharmacoeconomic evaluations of antifungal therapies, Curr Med Res Opin, vol.25, issue.7, pp.1751-1759, 2009. ,
Antimicrobial Drug Resistance in Taiwan, Journal of the Formosan Medical Association, vol.110, issue.1, pp.4-13, 2011. ,
DOI : 10.1016/S0929-6646(11)60002-8
The changing face of epidemiology of invasive fungal disease in Europe, Mycoses, vol.11, issue.3, pp.197-205, 2009. ,
DOI : 10.1111/j.1439-0507.2009.01691.x
Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention, Infectious Disease Clinics of North America, vol.25, issue.1, pp.201-226, 2011. ,
DOI : 10.1016/j.idc.2010.11.003
Guidelines for the prevention of invasive mould disease caused by filamentous fungi by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) Clin Microbiol Infcet, 2011. ,
Candidiasis invasoras en el paciente cr??tico adulto, Revista chilena de infectolog??a, vol.28, issue.1, pp.41-50, 2011. ,
DOI : 10.4067/S0716-10182011000100008
Tratamiento combinado de la aspergilosis invasora. ??Una oportunidad para micafungina?, Enfermedades Infecciosas y Microbiolog??a Cl??nica, vol.29, issue.2, pp.38-42, 2011. ,
DOI : 10.1016/S0213-005X(11)70008-8
Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology, Journal of Clinical Pharmacy and Therapeutics, vol.8, issue.Suppl. 1, pp.152-60, 2011. ,
DOI : 10.1111/j.1365-2710.2010.01166.x
Référentiel national de bon usage hors GHS antifongiques http://www.afssaps.fr/Dossiersthematiques/Tarification-a-l-activite-T2A-des medicaments, p.2, 2008. ,
Antifungal therapy in leukemia patients, Update of the ECIL 1 and ECIL 2 Guidelines. Third European conference on infections in leukemia, 2009. ,
Empirical antifungal therapy 2009 Update of the ECIL 1 and ECIL 2 Guidelines, Third European conference on infections in leukemia, 2009. ,
Antifungal prophylaxis in leukemia patients 2009 Update of the ECIL 1 and ECIL 2 Guidelines, Third European conference on infections in leukemia, 2009. ,
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America, Clinical Infectious Diseases, vol.46, issue.3, p.46, 2008. ,
DOI : 10.1086/525258
Clinical Practice Guidelines for the Management of Candidiasis, Update by the Infectious Diseases Society of America. CID, p.48, 2009. ,
Revue de??pertinence des??prescriptions des??nouveaux antifongiques syst??miques dans??un??h??pital universitaire, M??decine et Maladies Infectieuses, vol.37, pp.223-231, 2007. ,
DOI : 10.1016/j.medmal.2007.05.009
Candidoses invasives en r??animation??: analyse des traitements antifongiques au cours de l???enqu??te fran??aise AmarCand, Annales Fran??aises d'Anesth??sie et de R??animation, vol.27, issue.12, pp.999-1007, 2008. ,
DOI : 10.1016/j.annfar.2008.10.004
Prescribing new drugs: qualitative study of influences on consultants and general practitioners, BMJ, vol.323, issue.7309, pp.378-81, 2001. ,
DOI : 10.1136/bmj.323.7309.378
Why Don't Physicians Follow Clinical Practice Guidelines? A Framework for Improvement, Pediatric Research, vol.45, issue.4, Part 2 of 2, pp.1458-65, 1999. ,
DOI : 10.1203/00006450-199904020-00719
Effect of Exposure to Small Pharmaceutical Promotional Items on Treatment Preferences, Archives of Internal Medicine, vol.169, issue.9, pp.887-893, 2009. ,
DOI : 10.1001/archinternmed.2009.64
Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review, PLoS Medicine, vol.23, issue.5, 2011. ,
DOI : 10.1371/journal.pmed.1001037.s002
Successful medical treatment of Candida endocarditis with liposomal amphotericin B without surgical intervention, European Journal of Pediatrics, vol.119, issue.3, pp.469-470, 2008. ,
DOI : 10.1007/s00431-007-0498-8
A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections, Mycoses, vol.48, issue.3, pp.234-276, 2011. ,
DOI : 10.1111/j.1439-0507.2009.01808.x
Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients ? Cancer, pp.5290-5296, 2010. ,
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies, Cancer, vol.187, issue.12, pp.2740-2746, 2007. ,
DOI : 10.1002/cncr.23109
Analyse qualitative et quantitative des déterminants à l'application de recommandations ,